Short Interest in Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Declines By 63.6%

Posted by Francis Steltz on Aug 28th, 2026

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX – Get Free Report) was the recipient of a large decrease in short interest during the month of August. As of August 14th, there was short interest totaling 27,000 shares, a decrease of 63.6% from the July 30th total of 74,099 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average daily volume of 50,747 shares, the days-to-cover ratio is presently 0.5 days.

Radiopharm Theranostics Stock Up 6.6%

Shares of NASDAQ RADX traded up $0.15 during mid-day trading on Friday, hitting $2.41. The company’s stock had a trading volume of 333,279 shares, compared to its average volume of 101,031. Radiopharm Theranostics has a one year low of $2.04 and a one year high of $16.25. The company’s fifty day simple moving average is $3.55 and its 200-day simple moving average is $4.24.

Radiopharm Theranostics (NASDAQ:RADX – Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The company reported ($0.81) earnings per share for the quarter. The company had revenue of $0.49 million for the quarter. Equities analysts expect that Radiopharm Theranostics will post -2.36 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Friday, July 17th. HC Wainwright assumed coverage on shares of Radiopharm Theranostics in a report on Thursday, June 4th. They issued a “buy” rating and a $6.00 price target on the stock. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $11.00.

Get Our Latest Stock Analysis on RADX

Hedge Funds Weigh In On Radiopharm Theranostics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Marex Group plc acquired a new position in Radiopharm Theranostics in the fourth quarter valued at about $54,000. Jane Street Group LLC acquired a new stake in shares of Radiopharm Theranostics during the fourth quarter worth about $76,000. Virtu Financial LLC bought a new position in shares of Radiopharm Theranostics during the 4th quarter valued at about $76,000. Finally, Hsbc Holdings PLC bought a new position in shares of Radiopharm Theranostics during the 4th quarter valued at about $1,007,000.

About Radiopharm Theranostics

(Get Free Report)

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.